A collaborative, multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruption.
HIV
HIV cure research
HIV remission research
analytical treatment interruption
Journal
Journal of virus eradication
ISSN: 2055-6640
Titre abrégé: J Virus Erad
Pays: England
ID NLM: 101654142
Informations de publication
Date de publication:
20 Feb 2020
20 Feb 2020
Historique:
entrez:
17
3
2020
pubmed:
17
3
2020
medline:
17
3
2020
Statut:
epublish
Résumé
Analytic treatment interruptions (ATIs) are currently the standard for assessing the impact of experimental interventions aimed at inducing sustained antiretroviral therapy (ART)-free remission in trials related to HIV cure. ATIs are associated with substantial risk to both study participants and their sexual partner(s). Two documented HIV transmissions occurring in the context of ATIs have been recently reported, but recommendations for mitigating the risk of such events during ATIs are limited. We outline a practical approach to risk mitigation during ATI studies and describe strategies we are utilising in an upcoming clinical trial that may be applicable to other centres.
Types de publication
Editorial
Langues
eng
Pagination
34-37Subventions
Organisme : NIAID NIH HHS
ID : K23 AI134327
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027763
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH062246
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI126611
Pays : United States
Informations de copyright
© 2019 The Authors. Journal of Virus Eradication published by Mediscript.
Références
J Infect Dis. 2019 Jul 2;220(Supplement_1):S5-S6
pubmed: 30779842
Lancet HIV. 2018 Aug;5(8):e438-e447
pubmed: 30025681
AIDS Behav. 2008 Sep;12(5):713-20
pubmed: 17985229
J Infect Dis. 2018 Nov 5;218(12):1954-1963
pubmed: 30085241
J Infect Dis. 2019 Jul 2;220(Supplement_1):S7-S11
pubmed: 31264692
Lancet HIV. 2019 Apr;6(4):e259-e268
pubmed: 30885693
Curr HIV/AIDS Rep. 2019 Aug;16(4):259-269
pubmed: 31177363
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
J Infect Dis. 2019 Jul 2;220(Supplement_1):S12-S15
pubmed: 31264689
AIDS Res Hum Retroviruses. 2018 Jan;34(1):67-79
pubmed: 28562069
Curr Opin HIV AIDS. 2016 Jan;11(1):109-15
pubmed: 26633642
J Infect Dis. 2019 Nov 19;:
pubmed: 31742347
J Infect Dis. 2019 Jul 2;220(Supplement_1):S24-S26
pubmed: 31264691
Lancet. 2019 Jun 15;393(10189):2428-2438
pubmed: 31056293
Dev World Bioeth. 2013 Aug;13(2):87-94
pubmed: 23725227
J Infect Dis. 2019 Jul 2;220(Supplement_1):S1-S4
pubmed: 31264687
AIDS. 2019 Feb 1;33(2):279-284
pubmed: 30325777
JAMA. 2016 Jul 12;316(2):171-81
pubmed: 27404185
S Afr Med J. 2010 Jan;100(1):45-8
pubmed: 20429488
N Engl J Med. 2000 Mar 30;342(13):921-9
pubmed: 10738050
J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):96-101
pubmed: 16123689